Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Annelle Dugas

Nurse Practitioner Hattiesburg, MS Nurse Practitioner

NPI 1831555002 CMS profile 10883876

415 S 28Th Ave, Hattiesburg, MS 39401

Open in the dashboard

General payments

$3,718

201 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annelle Dugas of Hattiesburg, MS is reported in the CMS Open Payments database as having received $3,718 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $881 47
2024 General $745 44
2023 General $1,016 44
2022 General $888 54
2021 General $188 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annelle Dugas
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Annelle Dugas were reported at $881. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Annelle Dugas Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $188 $135 $40–$426 $132
2022 $888 $152 $48–$470 $149
2023 $1,016 $166 $54–$529 $160
2024 $745 $173 $55–$556 $164
2025 $881 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sumitomo Pharma America, Inc. $726 47 payments
  2. Janssen Biotech, Inc. $586 34 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $392 25 payments
  4. Accord Healthcare, Inc. $221 1 payment
  5. Teleflex LLC $187 5 payments
  6. Myriad Genetic Laboratories, Inc. $175 11 payments
  7. Urovant Sciences Inc $166 11 payments
  8. Dendreon Pharmaceuticals LLC $116 5 payments
  9. AbbVie, Inc. $97 6 payments
  10. Tolmar, Inc. $95 5 payments
  11. Other $957 51 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,718 201 payments
Products named General payments · program years 2021–2025
  1. GEMTESA $789 52 payments
  2. ERLEADA $586 34 payments
  3. Nubeqa $392 25 payments
  4. Xofigo $318 19 payments
  5. CAMCEVI $221 1 payment
  6. UROLIFT $160 4 payments
  7. Prolaris $158 10 payments
  8. PROVENGE $116 5 payments
  9. ELIGARD $112 6 payments
  10. ORGOVYX $103 6 payments
  11. Other $1,187 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

6,454

Median for Nurse Practitioner: 389

Drug cost

$499,359

Median for Nurse Practitioner: $21,885

Branded share of claims

27.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 322 $224,895
Myrbetriq Mirabegron Brand 263 $167,019
Tamsulosin Hcl Generic 2,133 $23,284
Trimethoprim Generic 252 $12,228
Methenamine Hippurate Generic 166 $11,643
Solifenacin Succinate Generic 356 $7,129
Oxybutynin Chloride Er Oxybutynin Chloride Brand 525 $6,946
Trospium Chloride Generic 122 $6,210
Finasteride Generic 458 $5,643
Mirabegron Er Mirabegron Brand 11 $5,206

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$173,666

Of which drugs: $26,071

Medicare patients

1,491

Average age 75

Services billed

25,283

417 women, 1,074 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 49%
Diabetes 38%
Chronic kidney disease 31%
Cancer 29%
Depression 24%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 15 120 $17,030
Injection, testosterone cypionate, 1 mg J1071 Office 12 18,350 $325

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $259
$259 322 —
ERLEADA
  • Janssen Biotech, Inc. $150
$150 — —
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $33
$33 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $32
$32 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record